Novel therapeutic strategies for the homozygous familial hypercholesterolemia

Recent Patents on Cardiovascular Drug Discovery

Volumn 8, Issue 2, 2013, Pages 143-150

  Mombelli, Giuliana ^a   Pavanello, Chiara ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Current treatments; Homozygous familial hypercholesterolemia; Mipomersen; MTP inhibitor Lomitapide; Patents; PCSK9 inhibitors

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN E; EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; MONOCLONAL ANTIBODY; SERINE PROTEINASE; SMALL INTERFERING RNA; VERY LOW DENSITY LIPOPROTEIN;

ANTIGEN BINDING; ANTISENSE THERAPY; AORTA STENOSIS; APHERESIS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO GENE TRANSFER; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; HIGH RISK PATIENT; HIGH RISK POPULATION; HOMOZYGOTE; HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; LIFESTYLE MODIFICATION; LIVER TRANSPLANTATION; LONG TERM EXPOSURE; LOSS OF FUNCTION MUTATION; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PLASMAPHERESIS; PORTOCAVAL SHUNT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; RARE DISEASE; SECONDARY PREVENTION; SURGICAL TECHNIQUE; XANTHOMA;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; RECEPTORS, LDL;

EID: 84888219087     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748901112079990001     Document Type: Article

References (55)

1. Soutar AK, Naoumova RP. Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-25.
2. Al-Allaf FA, Coutelle C, Waddington SN, David AL, Harbottle R, Themis M. LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives. Int Arch Med 2010; 3:36.
3. Marais AD. Familial hypercholesterolaemia. Clin Biochem Rev 2004; 25: 49-68.
4. Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA. Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 2001; 24: 52-5.
5. Raal FJ, Pappu AS, Illingworth DR, Pilcher GJ, Marais AD, Firth JC, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 2000; 150: 421-8.
6. Raal FJ, Pilcher GJ, Illingworth DR, Pappu AS, Stein EA, Laskarzewski P, et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 1997; 135: 249-56.
7. Naoumova RP, Thompson GR, Soutar AK. Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 2004;15: 413-22.
8. Marais AD, Raal FJ, Stein EA, Rader DJ, Blasetto J, Palmer M, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 2008; 197: 400-6.
9. Raal FJ, Pilcher GJ, Panz VR, van Deventer HE, Brice BC, Blom DJ, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipidlowering therapy. Circulation 2011;124: 2202-7.
10. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: Results of the NHLBI Type II Coronary Intervention Study. Circulation 1984; 69: 313-24.
11. Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208: 317-21.
12. Kolansky DM, Cuchel M, Clark BJ, Paridon S, McCrindle BW, Wiegers SE, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102: 1438-43.
13. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975; 1: 1208-11.
14. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res Ed) 1985; 291:1671-3.
15. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2:1005-7.
16. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 1987; 65:161-8.
17. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000;152: 519-26.
18. Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Longterm safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008;102:1199-204.
19. Palcoux JB, Atassi-Dumont M, Lefevre P, Hequet O, Schlienger JL, Brignon P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: Follow-up to 21 years. Ther Apher Dial 2008;12:195-201.
20. Thompson GR. Lipoprotein apheresis. Curr Opin Lipidol 2010; 21: 487-91.
21. Sibley C, Stone NJ. Familial hypercholesterolemia: A challenge of diagnosis and therapy. Cleve Clin J Med 2006; 73: 57-64.
22. Starzl TE, Bilheimer DW, Bahnson HT, Shaw BW, Jr., Hardesty RL, Griffith BP, et al. Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet 1984; 1:1382-3.
23. Kawagishi N, Satoh K, Akamatsu Y, Sekiguchi S, Ishigaki Y, Oikawa S, et al. Long-term outcome after living donor liver transplantation for two cases of homozygous familial hypercholesterolemia from a heterozygous donor. J Atheroscler Thromb 2007;14:94-8.
24. Shirahata Y, Ohkohchi N, Kawagishi N, Syouji M, Tsukamoto S, Sekiguchi S, et al. Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int 2003; 16: 276-9.
25. Kakaei F, Nikeghbalian S, Kazemi K, Salahi H, Bahador A, Dehghani SM, et al. Liver transplantation for homozygous familial hypercholesterolemia: Two case reports. Transplant Proc 2009; 41: 2939-41.
26. Castilla Cabezas JA, Lopez-Cillero P, Jimenez J, Fraga E, Arizon JM, Briceno J, et al. Role of orthotopic liver transplant in the treatment of homozygous familial hypercholesterolemia. Rev Esp Enferm Dig 2000; 92: 601-8.
27. Hoeg JM. The effect of portacaval shunt on hepatic lipoprotein metabolism in familial hypercholesterolemia. J Surg Res 1985; 39:369-77
28. Grossman M, Raper SE, Kozarsky K, Stein EA, Engelhardt JF, Muller D, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-41.
29. Grossman M, Rader DJ, Muller DW, Kolansky DM, Kozarsky K, Clark BJ 3rd, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med. 1995;1:1148-54.
30. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-6.
31. Cohen JC, Boerwinkle E, Mosley TH, Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-72.
32. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-18.
33. AMGEN. Clinical Trials. Available from: http://www.amgentrials.com/amgen/
34. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal F. Trial evaluating AMG 145, a PCSK9 antibody, in patients with homozygous FH: results of an initial dose-scheduling study. European Atherosclerosis Society 2013 2-5 June; Lyon, France.
35. Wierzbicki AS, Hardman TC, Viljoen A. Inhibition of pro-protein convertase subtilisin kexin 9 [corrected] (PCSK-9) as a treatment for hyperlipidaemia. Expert Opin Investig Drugs 2012; 21: 667-76.
36. Akinc, A., Fitzgerald, K., Hinkle, G., Milstein, S. Lipid formulated dsRNA targeting the PCSK9 gene. US8273869B2 (2012).
37. Jackson, S.M., King, C.T., Shan, B., Shen, W. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9). US8030457B2 (2011).
38. Jackson, S.M., Clinton, W.N.P., Piper, D.E., Shan, B., Shen, W., Chan, J., King, C.T., Ketchem, R.R., Mehlin, C., Carabeo, T.A., Cao, Q. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9). US20130085265A1(2013).
39. Condra, J.H., Cubbon, R.M., Hammond, H.A., McCabe, T., Pandit, S., Peterson, L.B., Santoro, J.C., Sitlani, A., Wood, D.D., Mach, H., Yoder, H., Gregory, S.M., Blue, J.T., Wang, K., Luo, P., Nawrocki, D.K., Zhong, P., Dong, F., Li, Y. 1b20 pcsk9 antagonists. US20130071379A1 (2013).
40. Crooke RBB, Wedel M. Cardiovascular therapeutic applications. In: Crooke ST-Antisense drug technology: Principles, streategies and applications. 2 ed. Boca Raton: CRC Press 2007; 601-39.
41. United States Food and Drug Administration. In: Press Announcements 337195
42. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, Cromwell WC, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
43. FDA. Briefing Document. NDA 203568. Mipomersen sodium injection 200 mg/mL. In; 2012.
44. Crooke, R.M., Graham, M.J. Antisense modulation of apolipoprotein B expression. US7407943B2 (2008).
45. Crooke, R.M., Freier, S.M., Graham, M. Antisense modulation of apolipoprotein B expression. US7511131B2 (2009).
46. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148-56.
47. Hussain MM, Iqbal J, Anwar K, Rava P, Dai K. Microsomal triglyceride transfer protein: A multifunctional protein. Front Biosci 2003; 8:500-6.
48. Cuchel M, Meagher EA, du Toit TH, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study. Lancet 2013; 381: 40-6.
49. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci 2008; 115: 141-150.
50. Santos RD. Lipid-lowering treatment for homozygous familial hypercholesterolaemia. Lancet 2013;381:1182
51. Cuchel M, Rader DJ. Lipid-lowering treatment for homozygous familial hypercholesterolaemia-Authors' reply. Lancet 2013;381:1183.
52. Rader D.J. Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects. US7932268B2 (2011).
53. Wierzbicki AS, Hardman TC, Viljoen A. New lipid-lowering drugs: an update. Int J Clin Pract 2012; 66: 270-80.
54. Parhofer KG. Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia. Core Evid 2012;7: 29-38.
55. Daniels SR, Gidding SS, de Ferranti SD. National Lipid Association Expert Panel on Familial H. Pediatric aspects of familial hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S30-7.